Quick answer: latest quarter results, by ticker or company name

Reported Q: Q1 2025 Rev YoY: +21.6% EPS YoY: -23.1% Move: -77.36%

Lexaria Bioscience Corp

LEXXW

$0.00120 -77.36%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q1 2025

Published: Jan 10, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for LEXXW

Reported

Report Date

Jan 10, 2025

Quarter Q1 2025

Revenue

183.92K

YoY: +21.6%

EPS

-0.16

YoY: -23.1%

Market Move

-77.36%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $0.18M up 21.6% year-over-year
EPS of $-0.16 decreased by 23.1% from previous year
Gross margin of 98.5%
Net income of -2.70M
"N/A" - N/A

LEXXW

Company LEXXW

Period Q1 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 11, 2026

Executive Summary

Lexaria Bioscience Corp (LEXXW) reported QQ1 2025 results that feature a meaningful sequential revenue uplift but continued operating losses driven by aggressive R&D outlays. Revenue rose 21.6% year-over-year to $183,923 and 118.96% quarter-over-quarter from the Q4 2024 level of $84,000, underscoring the company’s reliance on out-licensing and technology development in a capital-light model. The gross margin remains exceptionally strong at ~98.5% due to a very low cost of revenue, while operating expenses swelled to $2.87 million as R&D accounted for the largest share of spend, signaling an ongoing push to build licensing and product pipelines for DehydraTECH.

Key Performance Indicators

Revenue

Increasing

183.92K

QoQ: 118.96% | YoY: 21.58%

Gross Profit

Increasing

181.20K

98.52% margin

QoQ: 115.72% | YoY: 23.73%

Operating Income

Decreasing

-2.69M

QoQ: -22.13% | YoY: -136.20%

Net Income

Decreasing

-2.70M

QoQ: -23.75% | YoY: -129.26%

EPS

Decreasing

-0.16

QoQ: 5.88% | YoY: -23.08%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: $183,923; YoY +21.6%, QoQ +118.96% | Gross Profit: $181,203; YoY +23.73%, QoQ +115.72% | Operating Income: -$2,690,707; YoY -136.20%, QoQ -22.13% | Net Income: -$2,703,699; YoY -129.26%, QoQ -23.75% | EPS: -$0.16; YoY -23.08%, QoQ +5.88% | Gross Margin: 98.5%, Operating Margin: -14.63%, Net Margin: -14.70% | EBITDA: -$2,690,707 | Weighted Avg Shares: 16.668M; Cash from Operations: -$2.726M; Free Cash Flow: -$2.726M | Cash End of Period: $8.078M; Cash Beginning: $6.500M; Net Change in Cash: +$1.579M | Total Current Assets: $8.825M; Total Assets: $9.794M; Total Liabilities: $0.400M; Total Stockholders’ Equity: $9.774M | Cash and Cash Equivalents: $8.078M; Net Debt: -$7.948M

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	183.92K	21.58%	118.96%
Gross Profit	181.20K	23.73%	115.72%
Operating Income	-2.69M	-136.20%	-22.13%
Net Income	-2.70M	-129.26%	-23.75%
EPS	-0.16	-23.08%	5.88%

Key Financial Ratios

Gross Profit Margin

Excellent

98.50%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Weak

-14.63%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-14.70%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.28%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.28%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

29.64

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.01

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-3.21x

Negative earnings make P/E ratio not meaningful

Price to Book

Premium

3.55x

Trading at premium to book value, reflects strong intangibles or growth

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2025	0.17	-0.15	+20.0%	View
Q1 2025	0.18	-0.16	+21.6%	View
Q4 2024	0.08	-0.17	+2.0%	View
Q3 2024	0.08	-0.13	-9.8%	View
Q2 2024	0.15	-0.06	+55.7%	View

LEXXW

Lexaria Bioscience Corp

Q2 2025 Report

Lexaria Bioscience Corp (LEXXW) QQ2 2025 Results – Modest Revenue, High R&D Spend, and Solid Liquidity Supports a Narrow License-Based Growth Path...

Read full report

LEXXW

Lexaria Bioscience Corp

Q4 2024 Report

Lexaria Bioscience Corp (LEXXW) QQ4 2024 Results Analysis — Licensing-Driven Revenue, Significant R&D Invested, Solid Cash Position in a High-Burn B...

Read full report

LEXXW

Lexaria Bioscience Corp

Q3 2024 Report

Lexaria Bioscience Corp (LEXXW) QQ3 2024 Results – Cash Rich Yet Low Revenue in a High-Burn Biotech Licence Play...

Read full report

LEXXW

Lexaria Bioscience Corp

Q2 2024 Report

Lexaria Bioscience Corp (LEXXW) QQ2 2024 Financial Results: Liquidity cushion, lean revenue base, and path to DehydraTECH monetization...

Read full report

Lexaria Bioscience Corp (LEXXW) Q1 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More LEXXW Quarterly Reports

LEXXW

LEXXW

LEXXW

LEXXW

Q1 2025 Reports in Healthcare Sector

LEXX

Related Financial Data

Sector Analysis: Healthcare

LEXXW Full Profile

LEXXW Financial Statements

Earnings Calendar